Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)

Subclass of:

435 - Chemistry: molecular biology and microbiology

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130040383Nucleic acid molecules encoding anti-inflammatory domain antibodies - The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.02-14-2013
20130040384CIRCULAR PERMUTANT GFP INSERTION FOLDING REPORTERS - Provided are methods of assaying and improving protein folding using circular permutants of fluorescent proteins, including circular permutants of GFP variants and combinations thereof. The invention further provides various nucleic acid molecules and vectors incorporating such nucleic acid molecules, comprising polynucleotides encoding fluorescent protein circular permutants derived from superfolder GFP, which polynucleotides include an internal cloning site into which a heterologous polynucleotide may be inserted in-frame with the circular permutant coding sequence, and which when expressed are capable of reporting on the degree to which a polypeptide encoded by such an inserted heterologous polynucleotide is correctly folded by correlation with the degree of fluorescence exhibited.02-14-2013
20110207210Isolated or synthesized Rhopalosiphum padi virus polynucleotides having a promotor activity - Provided herein are isolated or synthesized Rhopalosiphum padi virus (RhPV) nucleic acids having promotor activities, and vectors containing the isolated or synthesized RhPV nucleic acids for gene delivery in insect expression systems.08-25-2011
20080261300Synthetic genes - The invention provides strategies, methods, vectors, reagents, and systems for production of synthetic genes, production of libraries of such genes, and manipulation and characterization of the genes and corresponding encoded polypeptides. In one aspect, the synthetic genes can encode polyketide synthase polypeptides and facilitate production of therapeutically or commercially important polyketide compounds.10-23-2008
20090191623COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION WITH CUPREDOXIN AND CYTOCHROME C - The present invention relates to cupredoxin, specifically 07-30-2009
20100081193Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis - Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.04-01-2010
20120178156GENETIC VARIANT OF THE ANNEXIN A5 GENE - The present invention relates to a nucleic acid molecule comprising an annexin A5 (ANXA5) gene regulation element which comprises at least one point mutation, corresponding to nucleotide 186 (G to A), 203 (A to C), 229 (T to C), and 276 (G to A) of SEQ ID NO: 2, a vector comprising the nucleic acid molecule, and a host transformed with the vector. The invention also relates to specific uses, in particular diagnostic uses of the nucleic acid molecules described herein. The invention also relates to haplotyping an ANXA5 gene regulation element from a nucleic acid from an individual which involves determining nucleotides present at positions 186, 203, 229 and 276 of the individual's copy of the ANXA5 gene regulation element, by comparison to SEQ ID NO: 2.07-12-2012
20130078716VCP-Based Vectors for Algal Cell Transformation - Provided herein are exemplary vectors for transforming algal cells. In exemplary embodiments, the vector comprises a Violaxanthin-chlorophyll a binding protein (Vcp) promoter driving expression of an antibiotic resistance gene in an algal cell. Embodiments of the invention may be used to introduce a gene (or genes) into the alga 03-28-2013
20130078715Anti-MicroRNA Oligonucleotide Molecules - The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.03-28-2013
20100112685Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities - The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties. Also provided are vectors suitable for expressing such DNA molecules, as well as methods for utilizing such vectors.05-06-2010
20100009434Method for the Selective Enrichment of Double-Stranded Dna from Nucleic Acid Mixtures - The invention relates to a method for stripping undesired nucleic acid components from double-stranded DNA, in particular, super-coiled plasmid DNA. The method according to the invention is characterised by the steps: (a) provision of a mixture containing completely and/or partly double-stranded nucleic acids and optionally single-stranded nucleic acids; (b) resuspension of the mixture from step (a) in an aqueous, low-molarity buffer system with low ionic strength and low buffer effect; (c) adjusting conditions in the mixture from step (b), under which the completely and/or partly double-stranded nucleic acids are denatured; (d) further addition of buffer and a polymer component to the mixture from step (c); (e) incubation of the mixture from step (d) for a time which is sufficient for the formation of an aqueous two-phase system with an upper and lower phase; and (f) removal of the upper phase containing the single-strand nucleic acid and collection of the double-strand nucleic acid from the lower phase.01-14-2010
20100144028Method And Device For Continuous Membrane Adsorption - A method and system is provided for yielding biopharmaceutical products involving a chromatographic separation process. The method comprises: providing a plurality of membrane adsorber cartridges; providing a plurality of valves, communicatively coupled to said plurality of membrane adsorber cartridges; and switching the valves, so as to interconnect said membrane adsorber cartridges to operate in a countercurrent flow mode. The system comprises multiple membrane adsorber cartridges that are interconnected and configured to operate in a countercurrent flow mode. Furthermore, the configuration comprises a valve assembly that allows the cartridges to be subjected to different steps in the process by automatic switching of the valves. In this way, cartridges are recycled many times during the purification of a batch.06-10-2010
20090098647Recombinant antigens for the detection of coxiella burnetii - The invention relates to a method for the detection of prior exposure to 04-16-2009
20090325284VIRUS PURIFICATION - A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.12-31-2009
20090042282PREPARATION OF PROTECTIVE ANTIGEN - A polynucleotide sequence is provided comprising a nucleic acid sequence encoding recombinant Protective Antigen (rPA).02-12-2009
20110003378MULTIPLE PROMOTER EXPRESSION CASSETTES FOR SIMULTANEOUS DELIVERY OF RNAi AGENTS - The present invention provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo.01-06-2011
20090305398Recombinant Double-Stranded RNA Phage, and Use of the Same - A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Methods are provided to deliver recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or polylactide-coglycolide, or by utilizing a bacterial vaccine vector.12-10-2009
20130164837VECTORS FOR DIRECTIONAL CLONING - The invention provides vectors and methods for directional cloning.06-27-2013
20110065174HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.03-17-2011
20110065173Vector - A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.03-17-2011
20110020926NOVEL TASTE-MODIFYING POLYPEPTIDE NAS, DNA THEREOF AND USE THEREOF - Disclosed is a polypeptide shown below in (A) or (B), a protein dimer neoculin comprising the polypeptide Neoculin Acidic Subunit (NAS) and the polypeptide Neoculin Basic Subunit (NBS) and having a taste-modifying activity: 01-27-2011
20110020925NEW MODULATING MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM - The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.01-27-2011
20110020924HIGHLY PURE PLASMID DNA PREPARATIONS - The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants. The compositions described herein have a range of uses, including diverse applications in the field of bioterrorism, environmental science, food science, forensics, molecular biology, and health and medicine.01-27-2011
20090233352Method on Clinical Applications in Head Neck Cancer by Using DSG3 Molecule for Predicting Malignant Degree of Cancer, Serving as a Molecular Target and Using RNA Jamming Sequence on Inhibition-Specific of DSG3 Expression - The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.09-17-2009
20090047734METHOD OF SEPARATION OF DEOXYRIBONUCLEIC ACIDS - The present invention relates to a method of separating nucleic acids from a liquid, which comprises providing a mobile phase comprising nucleic acids and a first salt, which forms lyotropic ions when dissolved; passing said mobile phase across a hydrophobic interaction chromatography (HIC) matrix to adsorb deoxyribonucleic acid(s); passing an eluent across said matrix to desorb one or more deoxyribonucleic acid(s), which eluent comprises the first salt as well as an increasing gradient provided by a second salt, which second salt forms less lyotropic ions when dissolved than the first salt; and isolating at least one fraction comprising separated deoxyribonucleic acid(s).02-19-2009
20090047733Avidin-Pseudotyped Viral Vectors and Their Use - The present invention pertains to an avidin-pseudotyped virus, and especially baculovirus, useful for delivery of foreign genes etc. The present invention also pertains to vectors comprising respective cassettes for pseudotyping, mammalian gene expression and insect gene expression in baculovirus.02-19-2009
20120115220Anti-MicroRNA Oligonucleotide Molecules - The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.05-10-2012
20100086995MHC CLASS I PEPTIDE EPITOPES FROM THE HUMAN 5T4 TUMOR-ASSOCIATED ANTIGEN - There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.04-08-2010
20120270311FEMALE SPECIFIC INSECT EXPRESSION SYSTEM - The present invention provides an insect expression system that may be used to provide biological control of pest insects and control transmission of infectious diseases transmitted to the human population by insects.10-25-2012
20110117643Recombinant Expression Vector for Animal Cell - The present invention relates to a recombinant expression vector for an animal cell containing a dihydrofolate reductase (DHFR) coding nucleotide sequence operatively linked to a DHFR promoter, to an animal cell line transformed by the vector, and to a method for preparing a target protein using the same. As compared with existing animal cell expression vectors, the vector of the present invention enables an effective screening of a cell line clone in which foreign genes are amplified together with DHFR genes even at a much lower methotrexate concentration. The present invention exhibits excellent effects in cell line preparation as high-productivity cell lines can be ensured in a short time through the use of a lower concentration of methotrexate in the process of protein production cell line establishment.05-19-2011
20100047903METHODS OF PROCESSING COMPOSITIONS CONTAINING MICROPARTICLES - Methods for processing microparticles involve providing a composition comprising a plurality of solid microparticles and at least one non-volatile material, providing a non-solvent, and exposing the composition to the non-solvent to remove at least a portion of the non-volatile material from the composition while retaining at least the microparticles.02-25-2010
20090280560Yeast cell surface display of proteins and uses thereof - The present invention provides a genetic method for tethering polypeptides to the yeast cell wall in a form accessible for binding to macromolecules. Combining this method with fluorescence-activated cell sorting provides a means of selecting proteins with increased or decreased affinity for another molecule, altered specificity, or conditional binding. Also provided is a method for genetic fusion of the N terminus of a polypeptide of interest to the C-terminus of the yeast Aga2p cell wall protein. The outer wall of each yeast cell can display approximately 1011-12-2009
20100015698Human Chondroitinase Glycoprotein (CHASEGP), Process for Preparing the Same, and Pharmaceutical Compositions Comprising Thereof - The invention relates to the discovery of novel Chondroitinase Glycoproteins (CHASEGPs), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.01-21-2010
20100015700USE OF THE ADENOVIRAL E2 LATE PROMOTER - The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes, genes and nucleic acids which are respectively different from adenoviral nucleic acid controlled by an E2 late promoter. The invention also relates to the uses of said nucleic acid construct.01-21-2010
20110281347Multivalent vaccines comprising recombinant viral vectors - Described are vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Also described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.11-17-2011
20110287532EXPRESSION OF FACTOR IX IN GENE THERAPY VECTORS - Two mechanisms are provided for improving the expression of Factor IX in gene therapy vectors. The first is the use of a specific Factor IX polynucleotide coding sequence designed for optimal expression. The second is the use of transcriptional regulatory regions minimized in size so that they can be used to express Factor IX, as well as any other gene of interest, in a size-constrained environment such as in a self complementary gene therapy vector system.11-24-2011
20100216231VECTORS FOR DIRECTIONAL CLONING - The invention provides vectors and methods for directional cloning.08-26-2010
20080280355Control of Gene Expression with the Use of a Transcription Attenuator - This invention relates to a system for the expression of heterologous genes, comprising an attenuator element which inhibits the elongation of the transcription of the heterologous genes, the expression of which is to be controlled, and two regulating modules which control the expression of the attenuator element. The invention also relates to the use of said expression system for the amplification of the expression of recombinant proteins, RNAs or apolipoproteins in bacteria. The invention further relates to vectors containing said expression system.11-13-2008
20090117649ISOLATED SOLUBLE CORTICOTROPIN RELEASING FACTOR RECEPTOR TYPE 2 (SCRFR2) - The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In certain aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand and CRFR receptors, including but not limited to CRFR2, CRFR1 and functional or signaling capable variants thereof.05-07-2009
20100003746Production of Lentiviral Vectors - The present invention is a method of generating a lentivirus vector, comprising cloning each of a leotivimus transfer construct, gag, pol, an envelope protein and rev respectively into the same or different baculoviruses, and transducing a producer cell with the or each baculovirus.01-07-2010
20120190106Promoter System for Regulatable Gene Expression in Mammalian Cells - The present invention is directed to a bidirectional human cytomegalovirus (hCMV) promoter that can be used to promote transcription on both strands of a double stranded DNA molecule. When used as part of a system that includes tet operator and the gene coding for the tet repressor, the promoter can be used to induce mammalian gene expression in a highly regulated way.07-26-2012
20110217766Methods of Producing Peptides in Plants and Peptides Produced Thereby - Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion are present. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are also present.09-08-2011
20090317904VCP-Based Vectors for Algal Cell Transformation - Provided herein are exemplary vectors for transforming algal cells. In exemplary embodiments, the vector comprises a Violaxanthin-chlorophyll a binding protein (Vcp) promoter driving expression of an antibiotic resistance gene in an algal cell. Embodiments of the invention may be used to introduce a gene (or genes) into the alga 12-24-2009
20100178696IN VIVO GENOME-WIDE MUTAGENESIS - Disclosed herein are compositions and methods for deleting or duplicating DNA in a mammalian genome. Also disclosed are compositions and methods for generating a random genome-wide chromosome rearrangement. Also disclosed are compositions and methods for streamlined construction of gene targeting vectors.07-15-2010
20100112686SHORT HAIRPIN RNAS FOR INHIBITION OF GENE EXPRESSION - Methods, compositions, and kits that include small hairpin RNA (shRNA) useful for inhibition of gene expression, such as viral-mediated gene expression, are described.05-06-2010
20090081776NUCLEIC ACID ENCODING A NOVEL RIBONUCLEASE HAVING AN AMINO ACID SEQUENCE MADE UP OF THE AMINO ACID SEQUENCE OF A KNOWN RIBONUCLEASE AND AN N-TERMINAL LEADER SEQUENCE THAT IS AT LEAST ONE RESIDUE LONG - A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue or leader sequence.03-26-2009
20090148935Application of RNA Interference Targeting DHFR Gene, to Cell for Protein Production - Biological materials are applied to a CHO cell or the like for producing a species of protein. The biological materials includes a first vector and a second vector, the first vector including a dhfr gene of a species of mammal and a gene of the species of protein, the second vector including a DNA fragment for inducing a RNA interference in the CHO cell to reduce expression of a dhfr gene of relevance in said CHO cell after the second vector is applied to the CHO cell. The dhfr gene of the species of mammal, or a dhfr gene of the CHO cell, or both constitute at least part of the dhfr gene of relevance after the first vector is applied to said CHO cell. The DNA fragment consists of nucleotides characterizing a segment of a dhfr gene of the CHO cell and a segment of a dhfr gene of the species of mammal.06-11-2009
20100120140TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.05-13-2010
20120034689MYCOBACTERIAL ANTIGENS EXPRESSED DURING LATENCY - A method is provided for identifying mycobacterial genes that are induced or up-regulated under culture conditions that are nutrient-starving and which maintain mycobacterial latency, said conditions being obtainable by batch fermentation of a mycobacterium for at least 20 days post-inoculation, when compared with culture conditions that are not nutrient-starving and which support exponential growth of said mycobacterium. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection.02-09-2012
20090286311DNA sequences for the expression of alloproteins - The present invention discloses an expression method for non-naturally-occurring amino acid-containing protein comprising: expressing in animal cells: (A) a mutant tyrosyl-tRNA synthetase that is a mutation of tyrosyl-tRNA synthetase originating in 11-19-2009
20120107923EXPRESSION VECTORS WHICH INHIBIT SYNTHESIS OF CATALASE AND USES THEREOF - Vector and application of a medicine/drug that inhibits the intake of alcohol for prolonged periods, by inhibiting the synthesis of brain catalase or by destroying the product that is generated when brain catalase acts upon ethyl alcohol.05-03-2012
20100081194CELLS HAVING CARDIAC GLYCOSIDE RESISTANCE - A recombinant Na+, K+-ATPase α1-subunit protein resistant to cardiac glycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained by alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.04-01-2010
20090258416POLYMER MICELLE COMPLEX INCLUDING NUCLEIC ACID - It is an object of the present invention to provide a polyion complex used as a non-viral gene vector, which achieves sufficiently high gene expression efficiency to a target cell. The polyion complex of the present invention comprises a block copolymer formed by binding polyethylene glycol to polycation via a disulfide group and a nucleic acid.10-15-2009
20110201103System For Synergetic Expression Of Multiple Small Functional RNA Elements - The present invention relates in general to microRNAs (miRNAs). More specifically, the invention relates to expression vectors comprising multiple miRNA families and clusters capable of targeting multiple oncogenic pathways.08-18-2011
20090004734Mutated Anti-CD22 Antibodies With Increased Affinity To CD22-Expressing Leukemia Cells - Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.01-01-2009
20090142829Recombinant Constructs And Their Use In Reducing Gene Expression - Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target RNA) which is in proximity to this suitable nucleic acid sequence.06-04-2009
20090275122POLYPEPTIDES HAVING COLANIC ACID-DEGRADING ACTIVITY - The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.11-05-2009
20080241917Vector For Delivering Target Substance Into Nucleus or Cell - It is intended to provide a vector for delivering a target substance into a nucleus or a cell. This object is achieved by providing a vector for delivering a target substance into a nucleus or a cell which comprises a lipid membrane structure having a lipid membrane containing an anionic lipid such as phosphatidic acid, cardiolipin, etc.10-02-2008
20080241915DNA CLONING VECTOR PLASMIDS AND METHODS FOR THEIR USE - The present invention is a group of cloning vector plasmids for use in constructing DNA molecules, such as transgenes, for the purpose of gene expression or analysis of gene expression. The present invention is also a method for using the cloning vector plasmids in a variable series of cloning steps to produce a final transgene product. The plasmid cloning vectors are engineered to minimize the amount of manipulation of DNA fragment components by the end user of the vectors and the methods for their use. Transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification.10-02-2008
20090215168Transcriptional control in alicyclobacillus acidocaldarius and associated genes, proteins, and methods - Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from 08-27-2009
20080280356Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site - Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.11-13-2008
20080280354Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus - The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.11-13-2008
20080305541Recombinant vectors for use in position-independent transgene expression within chromatin - The embodiments of the present invention are directed to discrete, cis-acting regulatory elements that include a barrier element, an insulating element, a silencing element, and matrix attachment regions (“MARs”). Additional embodiments of the present invention are directed to nucleic acid molecules that are useful for facilitating stable transgene expression within a chromatin environment. Additional embodiments of the present invention are directed to recombinant expression vectors including nucleic acid molecules of the present invention that can be incorporated into artificial chromosomes, eukaryotic cell-lines, non-human transgenic animals, and transgenic plants, to improve recombinant protein production in a broad range of eukaryotic hosts, and pharmaceutical compositions including nucleic acid molecules of the present invention that are also useful for gene therapy in the treatment of various genetic diseases.12-11-2008
20080274542Polypeptide - Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.11-06-2008
20080286860CANCER SPECIFIC PROMOTERS - The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase IIα and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.11-20-2008
20100248355METHODS FOR GENERATING HIGH TITER HELPER-FREE PREPARATIONS OF RELEASED RECOMBINANT AAV VECTORS - This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agent that affect viral infectivity and/or replication.09-30-2010
20100144025HLA-BINDING PEPTIDE, PRECURSOR THEREOF, DNA FRAGMENT AND RECOMBINANT VECTOR ENCODING THE SAME - There is provided an HLA-binding peptide being excellent in binding affinity to an HLA-A type molecule. An HLA-binding peptide capable of binding to an HLA-A type molecule, including one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 50, and being composed of 8 or more and 11 or less amino acid residues, is provided. All of the amino acid sequences are the amino acid sequences that are predicted to be capable of binding to an HLA-A molecule by using a prediction program utilizing an active learning method shown in FIG. 06-10-2010
20100144027PLACENTAL PROTEIN HAVING A REGULATING ACTION ON PROTEOLYTIC ACTIVITY AND ITS RELATED GENE - The present invention is intended to provide a novel pharmaceutical composition containing a protein that does not have a known protein motif structure but has proteolytic activity and regulating action on the activity of other proteases, cell invasiveness and smooth muscle contraction and relaxation, and is capable of treating, preventing and diagnosing various diseases. The invention provides a pharmaceutical composition for the treatment, prevention or diagnosis of a disease selected from the group consisting of perinatal diseases, infertility, cancer, nervous system diseases, inflammatory diseases, immune diseases, cardiovascular diseases, endocrine diseases, viral infections, bacterial infections and prion diseases, which contains a protein shown in Sequence listing 1 or an antibody specific thereto. Furthermore, the invention also provides a recombinant vector for the treatment, prevention or diagnosis of a disease selected from the group consisting of perinatal diseases, infertility, cancer, nervous system diseases, inflammatory diseases, immune diseases, cardiovascular diseases, endocrine diseases, viral infections, bacterial infections and prion diseases, which contains a gene shown in Sequence listing 2 and encoding the protein shown in Sequence listing 1 or a gene shown in Sequence listing 3 or 4, and being a splice variant thereof.06-10-2010
20110269225CRUSTACEAN EXPRESSION VECTOR - Methods and constructs for genetic manipulation of one or more of shrimp, shellfish, mollusks, and fish are disclosed. The nucleic acid construct includes a promoter and an internal ribosome entry site of an insect picomavirus, such as a cricket paralysis-like picomavirus. One or more open reading frames can be operably associated with one or both of the promoter and the internal ribosome entry site, and one or more proteins or protein subunits can be expressed upon introduction of the construct into a host cell, such as into a shrimp. Method for producing immortalized crustacean cell lines using enhancer elements derived from shrimp and/or shrimp viruses are also described.11-03-2011
20090087905VEGF-D polynucleotides and methods of use - VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.04-02-2009
20100144029Facilitating Protein Solubility by Use of Peptide Extensions - Expression vectors for expression of a protein or polypeptide of interest as a fusion product composed of the protein or polypeptide of interest fused at one terminus to a solubility enhancing peptide extension are provided. Sequences encoding the peptide extensions are provided. The invention further comprises antibodies which bind specifically to one or more of the solubility enhancing peptide extensions.06-10-2010
20090123999NUCLEOTIDE SEQUENCES INVOVLED IN PLANT DISEASE RESISTANCE - The present invention relates to methods for producing plants having enhanced disease resistance. NRC1 proteins and nucleic acid sequences encoding these are provided, as well as transgenic plants producing NRC1 proteins.05-14-2009
20090123998Signature encoding sequence for genetic preservation - The present invention describes a method for fabrication of nucleic acid-based medium for storage of socially valuable information. This medium offers the possibility of simple and efficient reproduction of the information and cm be used for preserving information over periods of time, far surpassing those currently achievable by information storage devices utilizing conventional media.05-14-2009
20090075370Vectors - The present invention relates to a polynucleotide comprising a nucleotide sequence encoding a retroviral gag protein, wherein the gag protein comprises a heterologous RNA binding domain capable of recognising a corresponding sequence in an RNA genome to facilitate packaging of the RNA genome into a retroviral vector particle.03-19-2009
20090004733POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE B POLYPEPTIDES, POLYPEPTIDES, AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.01-01-2009
20090186406DRE recombinase and recombinase systems employing DRE recombinase - The invention provides a Dre/rox recombinase system. In particular, the invention provides Dre polypeptides that can catalyze site-specific recombination at rox sites but not at lox sites. The Dre/rox system can be utilized in a number of genetic manipulations either alone or in combination with other recombinase systems.07-23-2009
20130217115PLASMID STANDARD FOR USE IN QUANTITATIVE ASSAYS USING FLUORESCENT QUANTITATIVE PCR - Disclosed is a plasmid standard for use in fluorescent quantitative PCR assays. More specifically, the present invention provides a plasmid standard as well as amplification primers and detection probes thereof for use in the detection of gene mutation and expression amount.08-22-2013
20090142828Methods and Compositions for Increasing Protein Yield from a Cell Culture - Disclosed herein are compositions and methods for increasing protein production from a cell culture. By switching the cells from a replicative to a productive state (RP switch), protein biosynthesis is extended. The productive state is a pseudo-senescent state. This pseudo-senescent state can be induced by transforming the cells with a vector expressing a cell cycle inhibitor. Expression of the cell cycle inhibitor within the cell, because it does not cause cell death, allows for cells to be maintained in culture for longer periods. The invention allows for controlled enhanced protein biosynthetic productivity of cell lines for commercial and research purposes.06-04-2009
20090081778NUCLEIC ACID ENCODING A FUSION PROTEIN INCORPORATING A CYSTEINIZED RIBONUCLEASE - A nucleic acid encodes a novel fusion protein. The fusion protein contains a cysteinized variant of an RNase disclosed in U.S. Pat. No. 6,239,257 B1.03-26-2009
20090081777NUCLEIC ACID ENCODING CYSTEINIZED RIBONUCLEASE TO WHICH A TARGETING MOIETY CAN BE CONJUGATED - A nucleic acid encodes a cysteinized RNase to which a targeting moiety can be conjugated.03-26-2009
20090191622SYNTHETIC NUCLEIC ACIDS FROM AQUATIC SPECIES - A synthetic nucleic acid molecule is provided that includes nucleotides of a coding region for a fluorescent polypeptide having a codon composition differing at more than 25% of the codons from a parent nucleic acid sequence encoding a fluorescent polypeptide. The synthetic nucleic acid molecule has at least 3-fold fewer transcription regulatory sequences relative to the average number of such sequences in the parent nucleic acid sequence. The polypeptide encoded by the synthetic nucleic acid molecule preferably has at least 85% sequence identity to the polypeptide encoded by the parent nucleic acid sequence.07-30-2009
20090104691NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A REDUCED SIDE EFFECT - The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector.04-23-2009
20080318311Encapsulated Bacteriophage Formulation - An encapsulated bacteriophage formulation and a method for preparing encapsulated bacteriophage formulation is provided. The method for producing the encapsulated bacteriophage composition involves injection of a molten coating substance comprising stearic acid and palmitic acid present at a ratio of 50:50, into a granulator chamber containing immobilized bacterio-phages. The immobilized bacteriophage are agitated by rotation of a base of the chamber and swept by a flow of air at a temperature of between 10° C. and 50° C.12-25-2008
20080293134Human Cancer Suppressor Gene, Protein Encoded Therein, Expression Vector Containing Same - Disclosed are a human cancer suppressor gene, a proteins encoded therein, an expression vectors containing the same, and a microorganism transformed with the vector. The genes of the present invention may be useful to diagnose and prevent the human cancers.11-27-2008
20110223656MicroRNAs and Uses Thereof - Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.09-15-2011
20090215167Cationic graft-copolymer for non-viral gene delivery vector - A cationic graft-copolymer for a non-viral gene delivery vector comprising a unit derived from a cationic derivative of a water-soluble linear polymers having a hydroxyl groups, namely, a cationic polysaccharide of the following formula (1) and the cationic derivative of polyvinylalcohol of the following formula (2) or the cationic derivative of the partial hydrolyzed polyvinylalcohol of the following formula (3) and a unit derived from a polymerizable olefin compound of the following formula (4)08-27-2009
20090221065COMPOSITION FOR SUPPRESSING THE EXPRESSION OF FUCOSYLTRANSFERASE - Disclosed is a means for reducing the expression amount of a FUT8 gene, reducing the expression amount of a FUT8 protein, and/or reducing the expression amount of a product produced by the action of FUT8.09-03-2009
20100151566RECOMBINANT ANTIBODIES AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) - The present invention deals with recombinant polypeptide molecules related to antibodies, that specifically recognize the human Vascular Endothelial Growth Factor A (VEGF-A), and interfere with its in vitro stimulatory effects and pro-angiogenic activity in vivo. These recombinant polypeptide molecules affect proliferation of human endothelial cells in vitro, subcutaneous angiogenesis in mice induced by Matrigel pellets that contain VEGF-A and the growth of human tumors transplanted in nude athymic mice. Several of these moleculas prevent choroideal neovascularization in a non human primate experimental model. These molecules can be employed for passive immunotherapy in pathological entities which have in its base an abnormal increase in blood vessels, as: age-related macular degeneration (wet variant), cancer and its metastases, neovascular glaucoma, diabetic and newborn retinopathies, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, organ transplant rejection, hemangioma, angiofibroma, and others.06-17-2010
20100248356hTERT GENE EXPRESSION REGULATORY GENE - Disclosed is a novel substance capable of regulating the expression of a telomerase reverse transcriptase gene in a cell of a mammal. A gene capable of regulating the expression of hTERT, comprising a nucleotide sequence depicted in SEQ ID No: 1 or 2. The expression of a telomerase reverse transcriptase gene can be inhibited by inhibiting the expression of the gene. By utilizing this mechanism, the expression of a telomerase reverse transcriptase gene can be regulated.09-30-2010
20100151567Nucleic Acids Useful in the Manufacture of Oil - Novel gene sequences from microalgae are disclosed, as well as novel gene sequences useful in the manufacture of triglyceride oils. Also disclosed are sequences and vectors that allow microalgae to be cultivated on sugar cane and sugar beets as a feedstock. In some embodiments, the vectors are useful for the purpose of performing targeted modifications to the nuclear genome of heterotrophic microalgae.06-17-2010
20090093049Methods of Identifying Synthetic Transcriptional and Translational Regulatory Elements, and Compositions Related to Same - Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.04-09-2009
20090093048PROMOTERS AND USAGE THEREOF - Promoters and usage thereof. Two promoters, acuF and hsp promoters, comprise the nucleotide sequences of SEQ ID NO: 1 and 2, respectively.04-09-2009
20100184204NOVEL GLYPHOSATE-N-ACETYLTRANSFERASE (GAT) GENES - Novel proteins are provided herein, including proteins capable of catalyzing the acetylation of glyphosate and other structurally related proteins. Also provided are novel polynucleotides capable of encoding these proteins, compositions that include one or more of these novel proteins and/or polynucleotides, recombinant cells and transgenic plants comprising these novel compounds, diversification methods involving the novel compounds, and methods of using the compounds. Some of the novel methods and compounds provided herein can be used to render an organism, such as a plant, resistant to glyphosate.07-22-2010
20100184206TARGETING PSEUDOTYPED RETROVIRAL VECTORS - The present invention relates to retroviral vectors, particularly lentiviral vectors, pseudotyped with Sindbis envelope and targeted to specific cell types via a targeting moiety linked to the envelope.07-22-2010
20100184207METHODS FOR PRODUCING INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC USES FOR SUCH MOLECULES - Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided.07-22-2010
20100261267Circular permutant GFP insertion folding reporters - Provided are methods of assaying and improving protein folding using circular permutants of fluorescent proteins, including circular permutants of GFP variants and combinations thereof. The invention further provides various nucleic acid molecules and vectors incorporating such nucleic acid molecules, comprising polynucleotides encoding fluorescent protein circular permutants derived from superfolder GFP, which polynucleotides include an internal cloning site into which a heterologous polynucleotide may be inserted in-frame with the circular permutant coding sequence, and which when expressed are capable of reporting on the degree to which a polypeptide encoded by such an inserted heterologous polynucleotide is correctly folded by correlation with the degree of fluorescence exhibited.10-14-2010
20100190243siRNA-MEDIATED GENE SILENCING WITH VIRAL VECTORS - The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors.07-29-2010
20100184208hTERT GENE EXPRESSION REGULATORY GENE - Disclosed is a novel substance capable of regulating the expression of a telomerase reverse transcriptase gene in a cell of a mammal A gene capable of regulating the expression of hTERT, comprising a nucleotide sequence depicted in SEQ ID No: 1 or 2. The expression of a telomerase reverse transcriptase gene can be inhibited by inhibiting the expression of the gene. By utilizing this mechanism, the expression of a telomerase reverse transcriptase gene can be regulated.07-22-2010
20090017531METHOD FOR ISOLATING PLASMIDS FROM SUSPENDED BACTERIAL OR YEAST CELLS - A method for isolating plasmids from suspended bacterial or yeast cells using a filter matrix, at least one lysing substance being added to the suspension and predamaging or completely lysing the predominant portion of the suspended cells, at least one conformation-altering substance being added to the suspension to alter the conformation of the plasmids to be isolated so as to promote retention of the cell components in or at the filter matrix. The suspension is thereupon moved through the filter matrix and the cells if not yet lysed then being lysed to completion upon contact with the filter matrix and the released plasmids being retained in or at the filter matrix.01-15-2009
20090017532Vector - A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.01-15-2009
20100255570Polymerase Chain Reaction Product-Cloning Vector Suitable to its Easy Production and Method for Producing the Same - The present invention relates to a PCR product cloning vector applicable directly to the cloning of a PCR product. More precisely, the present invention relates to a PCR product cloning vector designed to be effective in use for blue/white colony selection and produced based on the restriction enzyme treatment process to generate non- complementary unpaired single overhang and a method for producing the same. According to the method of the present invention, the PCR product cloning vector designed to be advantageous for blue/white cloning selection can be produced with improved efficiency compared with the convention method.10-07-2010
20100144026siRNA-mediated gene silencing with viral vectors - The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors.06-10-2010
20090075369Angiostatin Fragments and Method of Use - Fragments of an endothelial cell proliferation inhibitor and method of use therefor are provided. The endothelial proliferation inhibitor is a protein derived from plasminogen, or more specifically is an angiostatin fragment. The angiostatin fragments generally correspond to kringle structures occurring within the endothelial cell proliferation inhibitor. The endothelial cell inhibiting activity of these fragments provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated disease.03-19-2009
20090075368Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeensis - Diagnostic tools for serodiagnosing ehrlichiosis in mammals, particularly in members of the Canidae family and in humans are provided. The diagnostic tools are a group of outer membrane proteins of 03-19-2009
20100221820Use of triplex structure DNA in transferring nucleotide sequences - The invention concerns a recombinant vector characterised in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), said regions being of retroviral or retroviral-like origin, said vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retranscription regulating, expressing and packaging signals of retroviral or retroviral-like origin.09-02-2010
20090111175NUCLEIC ACID ENCODING A NOVEL RIBONUCLEASE HAVING AN AMINO ACID SEQUENCE MADE UP OF THE AMINO ACID SEQUENCE OF A KNOWN RIBONUCLEASE AND AN N-TERMINAL LEADER SEQUENCE - A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a leader sequence.04-30-2009
20110117642TRAP VECTORS AND GENE TRAPPING METHOD BY USING THE SAME - A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.05-19-2011
20100173405Double-Stranded Nucleic Acid Molecule Cancer Cell Proliferation Inhibitor and Pharmaceutical Agent Suitable for Prevention or Treatment of Uterine Cancer, Breast Cancer, and Bladder Cancer - A double-stranded nucleic acid molecule for suppressing the expression of at least one of COX7RP and Efp genes which includes (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 38 and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a); a cancer cell proliferation inhibitor with the double-stranded nucleic acid molecule and against at least one of uterine, breast and bladder cancer cells; and a pharmaceutical agent with the cancer cell proliferation inhibitor and against at least one of uterine, breast and bladder cancers.07-08-2010
20110008882SPECIFIC GRP78 EXPRESSION-INHIBITION RNAi SEQUENCE, MEDICINE THEREOF AND METHOD THEREOF - The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5′-AAGGATGGTTAATGATGCTGAGAA-3′ [SEQ. ID NO: 1] complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer.01-13-2011
20110008883MAMMALIAN CELL-BASED IMMUNOGLOBULIN DISPLAY LIBRARIES - Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.01-13-2011
20110033921BARDET-BIEDL SUSCEPTIBILITY GENE AND USES THEREOF - The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.02-10-2011
20110033920COMPOSITIONS AND METHODS FOR USE IN RECOMBINATIONAL CLONING OF NUCELIC ACIDS - The present invention relates generally to compositions and methods for use in recombinational cloning of nucleic acid molecules. In particular, the invention relates to nucleic acid molecules encoding one or more recombination sites or portions thereof, to nucleic acid molecules comprising one or more of these recombination site nucleotide sequences and optionally comprising one or more additional physical or functional nucleotide sequences. The invention also relates to vectors comprising the nucleic acid molecules of the invention, to host cells comprising the vectors or nucleic acid molecules of the invention, to methods of producing polypeptides using the nucleic acid molecules of the invention, and to polypeptides encoded by these nucleic acid molecules or produced by the methods of the invention. The invention also relates to antibodies that bind to one or more polypeptides of the invention or epitopes thereof. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments.02-10-2011
20110045584EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.02-24-2011
20100015699VECTORS AND METHODS FOR TISSUE SPECIFIC SYNTHESIS OF PROTEIN IN EGGS OF TRANSGENIC HENS - Vectors and methods are provided for introducing genetic material into cells of a chicken or other avian species. More particularly, vectors and methods are provided for transferring a transgene to an embryonic chicken cell, so as to create a transgenic hen wherein the transgene is expressed in the hen's oviduct and the transgene product is secreted in the hen's eggs and/or those of her offspring. In a preferred embodiment, the transgene product is secreted in the egg white.01-21-2010
20100221821METHODS AND COMPOSITIONS RELATED TO RIBOSWITCHES THAT CONTROL ALTERNATIVE SPLICING AND RNA PROCESSING - Disclosed are methods and compositions related to riboswitches that control alternative splicing.09-02-2010
20100261268Superoxide dismutase (SOD) gene and a method of identifying and cloning thereof - The present invention provides a superoxide dismutase gene from 10-14-2010
20100062523Expression of Class 2 Mannosidase and Class III Mannosidase in Lower Eukaryotic Cells - A method for producing human-like glycoproteins by expressing a Class 2 α-mannosidase having a substrate specificity for Manα1,3 and Manα1,6 glycosidic linkages in a lower eukaryote is disclosed. Hydrolysis of these linkages on oligosaccharides produces substrates for further N-glycan processing in the secretory pathway.03-11-2010
20120244613HUMAN MICRORNAS AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ ID NOs: 1-94; 281-374; 467-481; 497-522; or 549, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary. The invention further relates to modified single stranded microRNA molecules, isolated single stranded anti-microRNA molecules and isolated microRNP molecules. In another embodiment, the invention relates to a method for inhibiting microRNP activity in a cell.09-27-2012
20110097791Novel process, construct and conjugate for producing multiple nucleic acid copies - This invention provides inter alia an in vitro process for producing multiple specific nucleic acid copies in which the copies are produced under isostatic conditions, e.g., temperature, buffer and ionic strength, and independently of any requirement for introducing an intermediate structure for producing the copies. In other aspects, the invention provides in vitro processes for producing multiple specific nucleic acid copies in which the products are substantially free of any primer-coded sequences, such sequences having been substantially or all removed from the product to regenerate a primer binding site, thereby allowing new priming events to occur and multiple nucleic acid copies to be produced. This invention further provides a promoter-independent non-naturally occurring nucleic acid construct that produces a nucleic acid copy or copies without using or relying on any gene product that may be coded by the nucleic acid construct. Another aspect of this invention concerns a protein-nucleic acid construct in the form of a conjugate linked variously, e.g., covalent linkage, complementary nucleic acid base-pairing, nucleic acid binding proteins, or ligand receptor binding. Further disclosed in this invention is an in vivo process for producing a specific nucleic acid in which such a protein-nucleic acid construct conjugate is introduced into a cell. A still further aspect of the invention relates to a construct comprising a host promoter, second promoter and DNA sequence uniquely located on the construct. The host transcribes a sequence in the construct coding for a different RNA polymerase which after translation is capable of recognizing its cognate promoter and transcribing from a DNA sequence of interest in the construct with the cognate promoter oriented such that it does not promote transcription from the construct of the different RNA polymerase.04-28-2011
20090215164Recombinant gene of adenovirus vector and p53 gene for treating proliferative diseases - The invention relates to the application of a recombinant of adenovirus vector and human tumor suppressor p53 gene expression cassette for producing the medicine for treating proliferative disease. In particular the invention relates to the application of a recombinant of adenovirus vector and human tumor suppressor p53 gene expression cassette for producing the medicine for treating scar.08-27-2009
20110081717DOUBLE-STRANDED NUCLEIC ACID MOLECULE, CANCER CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL AGENT SUITABLE FOR PREVENTION OR TREATMENT OF CANCER - A double-stranded nucleic acid molecule including (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 21, and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a), wherein the double-stranded nucleic acid molecule is for suppressing the expression of at least one of APP and EBAG9 genes.04-07-2011
20110081718SYSTEM FOR PACKAGING HIGH-CAPACITY ADENOVIRUSES - The invention relates to a nuew system for production and packaging of high capacity adenoviral vectors which does not require the use of helper virues and which is characterized in that it integrates the adenoviral genes needed for the control, replication and packaging of the viral particuiles in the genome of a host cell, which results in the improvement of the long term stability of the production system.04-07-2011
20110070640OPTIMIZED HIGH YIELD SYNTHETIC PLASMIDS - One aspect of the current invention is an optimized synthetic mammalian expression plasmid with a mutated origin of replication (e.g. “mut” family of plasmids) comprising a therapeutic element, and a replication element. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.03-24-2011
20100297752MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed.11-25-2010
20100297751Non-Ribosomal Peptide Synthetases - Novel tailor-made artificial non-ribosomal peptide synthetases (NRPSs) for non-ribosomal synthesis and/or modification of peptides of a predetermined length and composition and/or for modification of individual amino acids are described. The fusion of building units of said peptide synthetases in particular linker regions makes it possible to specifically prepare by means of “modular molecule construction kits” NRPSs which are capable of synthesizing peptides of a desired structure.11-25-2010
20080248564NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES - The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.10-09-2008
20120202283FREEZE-DRIED PRODUCT FOR INTRODUCING NUCLEIC ACID, OLIGONUCLEIC ACID OR DERIVATIVE THEREOF - A freeze-dried product of a complex containing (i) a nucleic acid, an oligonucleic acid or a derivative thereof, (ii) polyethyleneimine and (iii) hyaluronic acid or chondroitin sulfate. The freeze-dried product can be used to introduce a nucleic acid or an oligonucleotide into a cell.08-09-2012
20120276623DNA REMOVAL IN TARGET MOLECULE PURIFICATION - Removal of genomic DNA from biological samples using cation exchange is described.11-01-2012
20080213878Novel human membrane proteins and polynucleotides encoding the same - Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.09-04-2008
20110053260RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRAL GENOME - The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.03-03-2011
20110053259RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRUS GENOME - The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.03-03-2011
20110053258Novel promoter sequence and the application thereof - The present invention provides a novel promoter sequence derived from a promoter of geminivirus, a eukaryotic virus, and has the characteristics of prokaryotic promoters. The isolated sequence includes SEQ ID NO: 5, which can drive the expression of foreign genes in prokaryotic cells to a high level utilizing the prokaryotic RNA polymerases. The present invention is a constitutive promoter which does not require the addition of external inducers to promote high-level gene expressions. The promoter activity of the present invention is 15-fold higher than the Rep gene promoter of geminivirus, which is also active in prokaryotic cells. Compared to the promoter activity of the standard constitutive prokaryotic promoter rrnB P1, the activity of the present invention is 11.1% higher. The activity of the present invention is additive when concatenated in the same polarity in the constructs, further enhancing the expression level of genes.03-03-2011
20110136221THYMIDINE KINASE MUTANTS AND FUSION PROTEINS HAVING THYMIDINE KINASE AND GUANYLATE KINASE ACTIVITIES - The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties. Also provided are vectors suitable for expressing such DNA molecules, as well as methods for utilizing such vectors.06-09-2011
20100330666Vectors and Methods for Tissue Specific Synthesis of Protein in Eggs of Transgenic Hens - Vectors and methods are provided for introducing genetic material into cells of a chicken or other avian species. More particularly, vectors and methods are provided for transferring a transgene to an embryonic chicken cell, so as to create a transgenic hen wherein the transgene is expressed in the hen's oviduct and the transgene product is secreted in the hen's eggs and/or those of her offspring. In a preferred embodiment, the transgene product is secreted in the egg white.12-30-2010
20090203121NUCLEIC ACID AGENTS FOR DOWNREGULATING H19, AND METHODS OF USING SAME - Isolated oligonucleotides capable of down-regulating H19 mRNA in cancer cells are disclosed, as well as pharmaceutical compositions that include the oligonucleotides and methods of treatment of cancer using them. Methods of treating cancer comprising administering agents capable of downregulating H19 mRNA in combination with an additional anti-cancer treatment are further disclosed.08-13-2009
20100190244RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen—turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.07-29-2010
20110189766Micrornas and uses thereof - Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.08-04-2011
20100028993METHODS OF PRODUCING PEPTIDES IN PLANTS AND PEPTIDES PRODUCED THEREBY - Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion are present. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are also present.02-04-2010
20090209032FEEDING BUFFERS, SYSTEMS, AND METHODS FOR IN VITRO SYNTHESIS OF BIOMOLECULES - Compositions, methods and kits for in vitro systems for synthesis of biomolecules such as polypeptides, are provided herein. Cell extracts that provide enhanced yields of soluble proteins using in vitro protein synthesis methods are provided. The invention also includes methods for producing high yields of proteins by the addition of a feeding solution that includes amino acids and an energy source to an ongoing in vitro synthesis system. The invention also includes methods of using a high-yield in vitro synthesis system to produce large quantities of proteins with incorporated labeled amino acids for analysis by methods such as by NMR. The invention further includes vectors for enhanced production of proteins from nucleic acid templates using in vitro synthesis systems.08-20-2009
20090215165High-level expression of recombinant antibody in a mammalian host cell - A mammalian host cell with a high-level expression of recombinant antibody containing a double-gene vector with gene optimized nucleotide sequences encoding the light and the heavy antibody chains. The double-gene vector itself. A process for enhancing the production of recombinant antibody in a mammalian host cell.08-27-2009
20110117641Plasmid DNA Isolation - The invention provides apparatus, reagents, and methods for rapidly isolating plasmid DNA from a bacterial alkaline lysate.05-19-2011
20110117640TUMOR ANTIGENS BFA4 AND BCY1 FOR PREVENTION AND / OR TREATMENT OF CANCER - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.05-19-2011
20100184205NUCLEIC ACIDS INVOLVED IN VIRAL INFECTION - Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.07-22-2010
20120040451MOLECULES ABLE TO MODULATE THE EXPRESSION OF AT LEAST A GENE INVOLVED IN DEGRADATIVE PATHWAYS AND USES THEREOF - A molecule being able to modulate the expression of at least a gene involved in degradative pathways so to enhance the cellular degradative pathways and prevent or antagonize the accumulation of toxic compounds in a cell and acting on a CLEAR element. Preferred molecules are: the TFEB protein, synthetic or biotechnological functional derivative thereof; chimeric molecule comprising the TFEB protein, synthetic or biotechnological functional derivative thereof; modulator of the TFEB protein activity and/or expression level. The molecule may be used in the treatment of neurodegenerative and/or lysosomal storage disorders.02-16-2012
20120231536CHIMERAL INTERNAL RIBOSOMAL ENTRY SITE SEQUENCE AND USES THEREOF - An improved baculovirus vector capable of expressing genes in mammalian or insect host cells, and the uses thereof are disclosed. The improved baculovirus vector includes in sequence: a promoter; a first nucleic acid operably linked to the promoter for expressing a first protein in the mammalian or insect host cells; a chimera internal ribosomal entry site (IRES) comprising a portion of an enterovirus (EV) IRES sequence at least 90% identical to SEQ ID NO: 1 and a portion of a 09-13-2012
20090291491Retroviral vectors - Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.11-26-2009
20120301955Modified messenger RNA stabilizing sequences for expressing genes in bacterial cells - The present invention relates to methods of producing a polypeptide having biological activity in a bacterial cell, comprising: (a) cultivating a bacterial host cell in a medium conducive for production of the polypeptide, wherein the bacterial host cell comprises a nucleic acid construct comprising a promoter region operably linked to a polynucleotide sequence encoding the polypeptide and a modified mRNA processing/stabilizing sequence located downstream of the promoter region and upstream of the ribosome binding site of the polynucleotide sequence encoding the polypeptide, wherein the modified mRNA processing/stabilizing sequence promotes higher expression of the polynucleotide sequence compared to an unmodified mRNA processing/stabilizing sequence; and (b) isolating the polypeptide having biological activity from the cultivation medium. The present invention also relates to such modified mRNA processing/stabilizing sequences, nucleic acid constructs, and bacterial host cells and to methods of obtaining such bacterial host cells.11-29-2012
20100330667CHIMERIC GFP-AEQUORIN AS BIOLUMINESCENT CA++ REPORTERS AT THE SINGLE CELL LEVEL - A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).12-30-2010
20110318827Cysteine-Free Efficient Technetium (Tc) or Rhenium (Re) Chelating Peptide Tags and Their Use - The present invention relates to a peptide tag which can be used to bind a Technetium (Tc) or Rhenium (Re) radionuclide to a protein of interest which comprises the peptide tag and allows the imaging of such a tagged protein. In particular the present invention relates to a peptide tag which chelates a Tc or Re atom but which does not comprise a Cysteine residue.12-29-2011
20110318826INOTROPIC ANTIBODIES AND THERAPEUTIC USES THEREOF - Antibodies binding to sites on the alpha-subunit of the (Na12-29-2011
20080241916Multiple Gene Expression For Engineering Novel Pathways And Hyperexpression Of Foreign Proteins in Plants - The present invention relates in part to a tobacco chloroplast transformation vector effective for stably transforming a tobacco plant to express a multi-gene operon.10-02-2008
20100081192EARLY PROSTATE CANCER ANTIGENS (EPCA), POLYNUCLEOTIDE SEQUENCES ENCODING THEM, AND THEIR USE - A novel prostate cancer marker is described that is found in cancerous and normal prostate cells of individuals that have prostate cancer but is not found in the prostate of individuals without prostate cancer. The marker also is present in normal tissue adjacent to tumor tissue in individuals having prostate cancer. The marker, however, is absent in the prostate of individuals without prostate cancer. Methods employing the novel prostate cancer marker of the invention to predict the occurrence of the prostate disease, monitor the progression of prostate cancer and effect the treatment of prostate cancer, also are described.04-01-2010
20100129901HEPATITIS C VIRUS VACCINE - The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.05-27-2010
20090124000Recombinant Vectors - Methods and materials are provided for integrating heterologous nucleic acids into the genome of a cell or virus without disrupting expression of genes adjacent to the insertion site.05-14-2009
20120208267System for Synergistic Expression of Multiple Small Functional RNA Elements - The present invention relates in general to microRNAs (miRNAs). More specifically, the invention relates to expression vectors comprising multiple miRNAs or families and, clusters capable of targeting multiple oncogenic pathways.08-16-2012
20110165669Anti-MicroRNA Oligonucleotide Molecules - The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.07-07-2011
20110165668MHC Class I Peptide Epitopes from the Human 5T4 Tumor-Associated Antigen - There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID NO: 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 4; (iv) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 5; (v) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 6; (vi) the minimal epitope from the amino acid sequence shown as SEQ ID NO: 7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.07-07-2011
20120115219High affinity binding site of HGFR and methods for identification of antagonists thereof - Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.05-10-2012
20120064620MODULAR DNA-BINDING DOMAINS AND METHODS OF USE - The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.03-15-2012
20090017530Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small-molecule regulator - The present invention relates to conditionally replicating viruses or pairs of viruses containing a gene switch that is activatable by transient heat or other proteotoxic stress in the presence or absence of a small molecule regulator. The gene switch controls the expression of a gene for a protein required for efficient viral replication and may also control the activity of a passenger gene.01-15-2009
20120070892DNA Virus MicroRNA and Methods for Inhibiting Same - The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.03-22-2012
20120070891INHIBITION-BASED HIGH-THROUGHPUT SCREEN STRATEGY FOR CELL CLONES - A method for screening cells with high level expression of a target protein is disclosed. The method includes introducing into a plurality of host cells a DNA construct that encodes both a target protein and an inhibitor to an endogenous selectable marker in the host cells, screening host cells harboring the DNA construct for the expression of the endogenous selectable marker, and isolating cells with reduced expression of the selectable marker. Also disclosed is a DNA construct configured to express both the target protein and the inhibitor inside the host cell.03-22-2012
20120070890TARGETED GENE MODIFICATION BY PARVOVIRAL VECTORS - This invention provides methods for obtaining targeted gene modification in vertebrate cells using parvoviral vectors, including adeno-associated virus (AAV). The parvoviral vectors used in the methods of the invention are capable of targeting a specific genetic modification to a preselected target locus in a cellular genome by homologous pairing.03-22-2012
20100062524METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTOR PRODUCTION SYSTEMS - The present invention provides HIV-derived lentivectors which are multiply modified to create highly safe, efficient, and potent vectors for expressing transgenes for gene therapy. The lentiviral vectors comprise various combinations of an inactive central polypurine tract, a stuffer sequence, which may encode drug susceptibility genes, and a mutated hairpin in the 5′ leader sequence that substantially abolishes replication. These elements are provided in conjunction with other features of lentiviral vectors, such as a self-inactivating configuration for biosaftey and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments for inherited and acquired disorders, gene-therapies for cancers and other disease, the creation of industrial and experimental production systems utilizing transformed cells, as well as for the study of basic cellular and genetic processes.03-11-2010
20130011916CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS - Nucleic acids comprising a nucleic acid moiety and two or more transfection enhancer elements (TEE's) according to the general formula (I): Hydrophobic moiety—pH-responsive hydrophilic moiety, wherein said pH sensitive hydrophilic moiety of said TEE is independently a weak acid having a pka of between 4 and 6.5 or is a zwitterionic structure comprising a combination of acidic groups with weak basis having a pKa of between 4.5 and 7.01-10-2013
20110091966Antiviral Peptide Against Hepatitis C Virus - Disclosed herein is a small peptide, LaR2C, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This invention demonstrates that human La protein interacts with the HCV IRES element both in vitro and in vivo and also shown that this interaction enhances the efficiency of viral RNA translation (Pudi et al, J of Biol Chem, 2003). La protein has three putative RNA recognition motifs (RRM1-3). It has been established that RRM2 binds with high affinity around the GCAC sequence near the initiator AUG and the binding induces a conformational change in the HCV IRES which is critical for the internal initiation of translation (Pudi et al, J of Biol Chem, 2004).04-21-2011
20120122205MODULAR DNA-BINDING DOMAINS AND METHODS OF USE - The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.05-17-2012
20120122203METHODS AND KITS TO GENERATE miRNA- AND SMALL RNA-EXPRESSING VECTORS, AND ITS APPLICATION TO DEVELOP LENTIVIRAL EXPRESSION LIBRARIES - The invention relates to novel expression systems for microRNAs (miRNAs) based on the expression of the sense and antisense strand from convergent promoters. The invention also provides a method for the direct cloning of small RNAs present in an RNA preparation by the direct ligation of the small RNAs present within the preparation to vectors. Interestingly, if the vectors contain convergent promoter regions, the vectors isolated according to the method of the invention can be used for the direct expression of the small RNA without the need of using the DNA encoding for the small RNA precursor molecule.05-17-2012
20120122204LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA - The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.05-17-2012
20100093076SOLUBLE IL-27 RECEPTOR - Polypeptides and proteins comprising an IL-27RA cytokine binding domain operably linked to an immunoglobulin Fc fragment are disclosed. The Fc fragment is a modified Fc fragment wherein amino acid residues at EU index postions 234, 235, and 237 have been substituted to reduce binding to FcγRI and amino acid residues at EU index positions 330 and 331 have been substituted to reduce complement fixation. The proteins can be used medicinally for modulating immune responses, such as within methods of treating autoimmune diseases.04-15-2010
20090130752BIODEGRADABLE POLY(DISULFIDE AMINE)S FOR GENE DELIVERY - Poly(disulfide amine)s, methods of making, and methods of use are described. Illustrative embodiments of the poly(disulfide amine)s include poly(CBA-DAE), poly(CBA-DAB), and poly(CBA-DAH). These compositions are made by Michael addition between N,N′-cystaminebisacrylamide and N-Boc-protected diamine monomers, followed by N-Boc deprotection. Complexes are formed by mixing the poly(disulfide amine)s with nucleic acid. Delivery of the nucleic acid into cells is carried out by contacting the cells with the nucleic acid/poly(disulfide amine) complexes.05-21-2009
20090130751REDUCTION OF OFF-TARGET RNA INTERFERENCE TOXICITY - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.05-21-2009
20110183412ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS - The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.07-28-2011
20120231537Highly Pure Plasmid DNA Preparations - The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that comprises purifying plasmid DNA by chromatography, treating the purified plasmid DNA with a polypeptide that digests colanic acid under conditions that digest the colonic acid, and separating the plasmid DNA from the digested colonic acid.09-13-2012
20120315696METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS - Described are methods for large-scale production of recombinant adenovirus 26, utilizing perfusion systems and infection at very high cell densities.12-13-2012
20120214228TAL EFFECTOR-MEDIATED DNA MODIFICATION - Materials and Methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.08-23-2012
20120135515METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS - Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.05-31-2012
20100173404Partial fragment of REIC/Dkk-3 gene and cancer therapeutic agent comprising the same - This invention provides an inducer of apoptosis in cancer cells comprising a fragment of the REIC/Dkk-3 gene and a cancer therapeutic agent comprising the same. This invention also provides a polynucleotide fragment encoding the REIC/Dkk-3 protein (a) or (b), which encodes a polypeptide having apoptosis activity: (a) a polynucleotide encoding a polypeptide comprising an amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2; or (b) a polynucleotide encoding a polypeptide comprising an amino acid sequence derived from the amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2 by substitution, deletion, or addition of 1 or several amino acids and having apoptosis activity.07-08-2010
20120252115METHODS AND DEVICES FOR NUCLEIC ACID PURIFICATION - The invention provides pipette tip columns and automated methods for the purification of nucleic acids such as plasmids from unclarified cell lysates containing cell debris as well as methods for making and using such columns. The columns typically include a bed of medium positioned in the pipette tip column, above a bottom frit and with an optional top frit.10-04-2012
20120252113USE OF TRIPLEX STRUCTURE DNA IN TRANSFERRING NUCLEOTIDE SEQUENCES - The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.10-04-2012
20120077265MicroRNA and Methods for Inhibiting Same - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.03-29-2012
20120077264METHODS FOR PLANT TRANSFORMATION USING SPECTINOMYCIN SELECTION - The present invention relates to methods and compositions for transforming soybean, corn, cotton, or canola explants using spectinomycin as a selective agent for transformation of the explants. The method may further comprise treatment of the explants with cytokinin during the transformation and regeneration process.03-29-2012
20120252114USE OF TRIPLEX STRUCTURE DNA IN TRANSFERRING NUCLEOTIDE SEQUENCES - The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.10-04-2012
20100047904MATERIALS, METHODS AND SYSTEMS FOR PURIFICATION AND/OR SEPARATION - Materials, methods and systems are provided for the purification, filtration and/or separation of certain molecules such as certain size biomolecules. Certain embodiments relate to supports containing at least one polymethacrylate polymer engineered to have certain pore diameters and other properties, and which can be functionally adapted to for certain purifications, filtrations and/or separations.02-25-2010
20120178157RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRAL GENOME - The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.07-12-2012
20100273254PROCESS FOR PURIFICATION OF PLASMID DNA - The invention relates to a process for purifying plasmid DNA. The invention also relates to a DNA product made by the process of the invention. The DNA product is suitable for pharmaceutical use.10-28-2010
20100009435SPECIFIC GRP78 EXPRESSION-INHIBITION RNAi SEQUENCE, MEDICINE THEREOF AND METHOD THEREOF - The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5′-AAGGATGGTTAATGATGCTGAGAA-3′ complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer.01-14-2010
20090068731Novel process, construct and conjugate for producing multiple nucleic acid copies - This invention provides inter alia an in vitro process for producing multiple specific nucleic acid copies in which the copies are produced under isostatic conditions, by degradation of primer sequences from extended primers, thereby allowing subsequent priming events on the same template.03-12-2009
20100297750POLYNUCLEOTIDE OR ANALOGUE THEREOF, AND GENE EXPRESSION REGULATION METHOD USING THE POLYNUCLEOTIDE OR THE ANALOGUE THEREOF - [Objective] To be provided is a gene expression regulation method of regulating expression of a target gene and regulating expression of a target gene product both positively and negatively.11-25-2010
20100291671Modified Viral Vector Particles - This invention relates to viral vector particles, including capsid proteins with an attachment site for the specific chemical modification of the vector particles. Furthermore, the invention relates to procedures for the production of these viral vector particles. Furthermore, the invention relates to the use of these viral vector particles as a therapeutic, prophylactic or diagnostic means in humans and primates as well as other vertebrates like cattle, pigs, birds, fish, or rodents.11-18-2010
20120225477VIRAL AND VIRAL ASSOCIATED MIRNAS AND USES THEREOF - Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.09-06-2012
20120083031METHOD FOR TRACING GRAM-NEGATIVE BACTERIA INSIDE ANIMAL MODEL USING STABLE AND BIOLUMINESCENCE-BASED EXPRESSION SYSTEM THEREFOR - A method of creating a biotechnological product and an efficient and stable bio-luminescence vector which could be used for tracking Gram-negative bacteria when distributing inside animal body are provided. Through conjugation, this auto-luminescence vector can be easily transmitted from bacteria to bacteria among Gram-negative bacteria, and may facilitate bacteria to be luminescence-labeled for subsequently analyzing the dynamic change of bio-luminescent bacteria within animal body in vivo. This system includes a lacZ promoter-driven IuxABCDE, a high copy number of ColE1 replicon, and a high plasmid stability of the conjugative and broad host-ranged plasmid pSE34 from 04-05-2012
20110124101METHODS AND DEVICES FOR PRODUCING BIOMOLECULES - A scalable process and device for producing a bio molecule, in particular pharmaceutical grade plasmid DNA is described. The process includes the steps of alkaline lysis, neutralization and clarification and can be further extended. For separating the lysate and the precipitate an improved floatation method is disclosed. This method is based on attachment of CO05-26-2011
20110124100TRANSLATION ENHANCER-ELEMENT DEPENDENT VECTOR SYSTEMS - A translation enhancer-driven positive feedback vector system is disclosed which is designed to facilitate identification of a Translational Enhancer Element (TEE) and to provide a means for overexpression of gene products. The system exploits both transcriptional and translational approaches to control the expression levels of genes and/or gene products. Methods are also disclosed for screening libraries of random nucleotide sequences to identify translational elements and for overproduction of proteins, which have uses in both research and industrial environments.05-26-2011
20110124099IKKALPHA AND IKKBETA SPECIFIC INHIBITORS - A method for modulating NF-κB dependent gene transcription in a cell comprised of modulating IKKα and IKKβ protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-κB dependent gene transcription.05-26-2011
20100136678METHODS OF DIAGNOSIS OF SPINAL MUSCULAR ATROPHY AND TREATMENTS THEREOF - Methods for treating SMA in a subject comprise administering to the subject a recombinant genetic vector comprising at least one copy of a Stathmin inhibitor. The inhibitor can be a Stathmin expression inhibitor. The inhibitor can be or can encode an antisense or RNAi nucleic acid, such as a siRNA or a shRNA. The copy can be a copy of a host-expressible Stathmin inhibitor or a copy of a host-expressible Stathmin expression inhibitor. Screening methods can comprise the following steps: providing a Stathmin binding agent and a cellular sample from a human subject at least suspected of either having SMA or having a low SMN protein-based condition; contacting the Stathmin binding agent with the cellular sample under conditions in which the agent can specifically bind to Stathmin present in the sample to form complexes, and removing non-specifically bound agent therefrom to leave remaining complexes, and detecting remaining complexes and comparing the level of complexes detected or of the corresponding Stathmin concentration that is present in the sample, to a control level determined from a healthy cellular sample. The detection of an elevated level of complexes or of Stathmin concentration provides a positive screening result.06-03-2010
20110003379CHIMERIC AUTOPROCESSING POLYPEPTIDES AND USES THEREOF - A chimeric polypeptide comprising an autoprocessing segment having an amino acid sequence being capable of auto-cleavage, a polynucleotide encoding such a polypeptide, and uses of such a polypeptide and such a polynucleotide are provided. a polynucleotide are provided.01-06-2011
20110045583INFECTIVITY-ENHANCED CONDITIONALLY-REPLICATIVE ADENOVIRUS AND USES THEREOF - A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.02-24-2011
20100203627LONG-TERM IN VIVO TRANSGENE EXPRESSION - Efficient and prolonged hCFTR expression is one of the major obstacles for cystic fibrosis lung therapy. hCFTR mRNA expression levels depend on eukaryotic expression cassette components, prokaryotic backbone elements, and the gene transfer method may also influence transcriptional silencing mechanisms. A codon-optimized and CpG-reduced human CFTR gene (CO-CFTR) was made. Various vector modifications were tested to facilitate extended duration of CO-CFTR expression. Insertion of an extended 3′BGH transcribed sequence (712 bp) in an inverted orientation produced prolonged expression of CO-CFTR expression at biologically relevant levels. Further studies revealed that prolonged CO-CFTR expression is dependant on the orientation of the extended BGH 3′ BGH transcribed sequence and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements.08-12-2010
20120088298IKKALPHA AND IKKBETA SPECIFIC INHIBITORS - A method for modulating NF-κB dependent gene transcription in a cell comprised of modulating IKKα and IKKβ protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-κB dependent gene transcription.04-12-2012
20120088297MYCOBACTERIAL ANTIGENS EXPRESSED UNDER LOW OXYGEN TENSION - A method is provided for identifying mycobacterial genes that are induced or up-regulated under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37° C. when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37° C. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection.04-12-2012
20110294204EXPRESSION SYSTEM - The present invention relates generally to methods and compositions for expression of polypeptides or delivery of interfering RNAs in various cell types.12-01-2011
20100167389SYNTHETIC EXPRESSION VECTORS FOR INSECT CELLS - The present invention is directed at optimized expression vectors for the expression of native-like heterologous proteins in insect cells. Compositions of the invention are nucleotide sequences representing elements of an expression vector that when combined results in enhanced expression and secretion of heterologous proteins. The elements include sequences that define transcriptional activators, core promoters, secretion signals, and 3′ untranslated regions that are functional in insect cells. The elements contained in the optimized vectors are all synthetically derived or are modified variants of naturally occurring insect sequences. The expression vectors are useful for the expression of native-like proteins when protein encoding nucleotide sequences are operatively linked to the vectors. These vectors can be used to transform insect cells, which can then be cultured to produce the desired protein product. The expressed native-like proteins can be used in diagnostic, vaccine or other applications requiring large amounts of high quality proteins.07-01-2010
20120149097NONVIRAL VECTORS FOR DELIVERING POLYNUCLEOTIDES TO TARGET TISSUE - Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal.06-14-2012
20120149096PRRS VIRUSES, INFECTIOUS CLONES, MUTANTS THEREOF, AND METHOD OF USE - The present invention provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to PRRS viruses such as VR-2332, Lelystad, or others, and optionally further including a deletion in a region of ORF1 that encodes the nsp2 polypeptide.06-14-2012
20120149095DNA PROMOTERS AND ANTHRAX VACCINES - The invention is related to intracellularly induced bacterial DNA promoters and vaccines against 06-14-2012
20130017596Polycistronic Vector for Human Induced Pluripotent Stem Cell Production - Methods of producing induced pluripotent stem (iPS) cells are provided. For example, a method of producing an iPS cell from a differentiated cell, which includes transforming the differentiated cell with a first vector comprising a nucleic acid sequence comprising a nucleic acid sequence encoding an Oct4, a nucleic acid sequence encoding a Sox2, and a nucleic acid sequence encoding a Klf4. Each of the nucleic acid sequences are separated from each other by a first and second viral 2A sequence. The method described can further comprise culturing the transformed cell under conditions that allow for the production of an iPS cell and isolating the cultured iPS cell.01-17-2013
20110159583MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter or a MN gene promoter fragment comprising the HIF-1 consensus binding sequence, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. Further, the hypoxia inducibility of the MN gene and the uses of such inducibility are disclosed.06-30-2011
20080254536Method of elevating photosynthesis speed of plant by improving pyruvate phosphate dikinase - The present invention relates to the transformation of C4 plants. It also relates to the high-level expression of foreign genes in C4 plants. More specifically, the present invention relates to the creation of C4 plants retaining an excellent photosynthetic capacity at low temperature by achieving high-level expression of an enzyme constituting the C4 photosynthetic pathway. In the present invention, C4 plants are transformed using an expression cassette that comprises a promoter, a C4 plant genomic gene, under control of said promoter, encoding an enzyme constituting a photosynthetic pathway, and a terminator. The C4 plant genomic gene encoding an enzyme constituting a photosynthetic pathway is preferably a C4 plant genome-derived PPDK gene or a modified form thereof. The present invention is particularly useful in improving the production of C4 plants having PPDK (especially, in improving the production of maize under low temperature conditions).10-16-2008
20130171726MULTIPLE PROMOTER EXPRESSION CASSETTES FOR SIMULTANEOUS DELIVERY OF RNAI AGENTS - The present invention provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo.07-04-2013
20090317903HUMANIZED ANTI-TAG 72 CC49 FOR DIAGNOSIS AND THERAPY OF HUMAN TUMORS - The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.12-24-2009
20090148936LENTIVIRAL VECTOR-MEDIATED GENE TRANSFER AND USES THEREOF - The present invention provides lentiviral vectors that are useful in human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated.06-11-2009
20110263012SCREENING AND THERAPEUTIC METHOD FOR NSCLC TARGETING CDCA1-KNTC2 COMPLEX - The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.10-27-2011
20080220519MUTATED E. COLI HEAT-LABILE ENTEROTOXIN - This invention relates to a mutant 09-11-2008
20080220518Method From the Selection of Biomolecules From Biomolecules Variant Libraries - The invention relates to a method from the selection of biomolecules from variant libraries, in particular of biocatalytically active biomolecules, comprising the steps: a) production of a variant library, b) division of the library into a number of compartments, which is smaller than the total number of variants in the variant library by a factor of at least 10, c) production and testing of the biomolecules in the individual compartments for a particular property, for example, a biocatalytic activity, d) selection of at least one compartment I in which there are biomolecules fulfilling the desired property, e) division of the partial library contained in the selected compartment into further compartments and f) n-fold repetition of the steps c) to e) until each compartment contains only one variant of the gene sequence coding for the biomolecule. In contrast to established methods which comprise mutagenesis and selection steps, said method starts with a large library in which the desired variant is contained from the outset.09-11-2008
20130177976COMBINATION OF CATIONIC POLYMERS AND POLYSACCHARIDES NANOPARTICLES AS A GENE CARRIER - The present invention discloses a gene carrier and the preparation method thereof. The chondroitin sulfate (CS) is reacted with methacrylic anhydride (MA) to form a chondroitin sulfate-methacrylate (CSMA), which is further covalently bound with 2-(dimethylamino)ethyl methacrylate (DMAEMA) to form the “CM-DM” gene carrier. The novel nonviral and lower cytotoxic gene delivery vector/carrier with the sugar functionality reduced the cytotoxicity of poly(2-dimethylaminoethyl methacrylate) (PDMAEMA), and can successfully deliver plasmid DNA to cancer cells via the caveolae-mediated and CD44-mediated endocytosis mechanisms.07-11-2013
20130115693DEVICE FOR ISOLATION AND/OR PURIFICATION OF BIOMOLECULES - The present invention refers to a device, comprising a hollow body having at least one open end comprising at least one solid matrix binding, adsorbing, absorbing, chelating or retaining compounds which are not desired in a sample and preferably at least one barrier which is non-permeable for liquids and solids under ambience conditions, however, becomes liquid-permeable by applying an external force to said barrier, the use of such a device for isolating or purifying a biomolecule from a sample, a method for preparation of said device and a method for isolation or purification of any biomolecule using said device.05-09-2013
20130115692METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTORS AND THEIR APPLICATIONS - The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.05-09-2013
20130130370MicroRNA and Methods for Inhibiting Same - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.05-23-2013
20080199952COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOCOCCAL INFECTION - The invention provides polypeptides, polysaccharide-polypeptide conjugates, and expression vectors for treating or preventing pneumococcal infection. The compositions induce an anti-pneumococcal immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response in an infected individual.08-21-2008
20130122582EXPRESSION VECTOR - A conventional shuttle vector constructed by fusing an 05-16-2013
20130143314THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS - The present invention provides improved methods and compositions based on microvesicles for the treatment of various diseases, disorders and conditions. In particular, the present invention encompasses the recognition that microvesicles contain specific microRNAs which may function as intercellular regulators involved in cell or tissue regeneration, remodeling, reconstruction, reprogramming or transdifferentiation. Thus, among other things, the present invention provides methods and compositions based on microvesicles and/or associated microRNAs that provide more predictable and effective therapeutic results.06-06-2013
20090215166Cationic Polymer for Transporting Nucleic Acids in Cells - The invention relates to a cationic polymer containing cationic oligomers cross-linkable by fissile linker sequences, wherein said cationic polymers form, together with nucleic acids, polyplexes and can be used for cell transfection and the invention is characterised in that the cationic polymer contains intracellular reductive or enzymatic fissile linker sequences.08-27-2009
20110275146FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS - The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-111-10-2011
20100317097SYNTHETIC MOLECULES THAT SPECIFICALLY REACT WITH TARGET SEQUENCES - The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.12-16-2010
20100317096Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site - Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.12-16-2010
20130157354TRANSGENIC NON-HUMAN ANIMALS FOR PRODUCING CHIMERIC ANTIBODIES - The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.06-20-2013
20120282687EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.11-08-2012
20120282686EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.11-08-2012
20120282685EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY - Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.11-08-2012
20130122581TAL EFFECTOR-MEDIATED DNA MODIFICATION - Materials and Methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.05-16-2013
20110312086MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE - The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.12-22-2011
20120021506Regulatory sequences for expressing gene products in plant reproductive tissue - Expression cassettes causing specific regulatory control of transgene expression in plants, wherein the expression cassettes include regulatory sequences from the MADS gene family for expression of recombinant gene products in the reproductive tissue of plants for the purpose of generating abiotic stress tolerant plants.01-26-2012
20120028348MULTIPLE RNA POLYMERASE III PROMOTER EXPRESSION CONSTRUCTS - Expression constructs comprising at least two different RNA polymerase III promoters, wherein each promoter is operably linked to a nucleic acid sequence encoding an RNA effector molecule, are disclosed herein. Further provided are expression constructs comprising multiple polymerase III promoters operably linked to sequences encoding short hairpin RNA molecules, which may comprise single and/or multiple fingers. The provided constructs are useful for in vivo delivery of RNA molecules effective in gene silencing, including of viral genes including HBV and HCV.02-02-2012
20120028347AGENT FOR SUPPRESSING REPLICATION OF HIV AND USE THEREOF - It is an object of the present invention to provide an agent for suppressing the replication of HIV, which comprises a human CD4-recognizing antibody. The object is solved by an agent for suppressing the replication of human immunodeficiency virus, which comprises, as an active ingredient, an antibody described in (1) below:02-02-2012
20120077266HIGHLY THERMOSTABLE FLUORESCENT PROTEINS - Thermostable fluorescent proteins (TSFPs), methods for generating these and other stability-enhanced proteins, polynucleotides encoding such proteins, and assays and method for using the TSFPs and TSFP-encoding nucleic acid molecules are provided. The TSFPs of the invention show extremely enhanced levels of stability and thermotolerance. In one case, for example, a TSFP of the invention is so stable it can be heated to 99° C. for short periods of time without denaturing, and retains 85% of its fluorescence when heated to 80° C. for several minutes. The invention also provides a method for generating stability-enhanced variants of a protein, including but not limited to fluorescent proteins.03-29-2012
20120094375ENHANCED ENGINEERED NATIVE PROMOTERS AND USES THEREOF - We describe methods and DNA constructs/engineered mammalian promoters to enhance native promoter activity while retaining inherent regulation by inserting multi-copy response elements (REs) into non-adjacent locations. Multiple copies of REs are clustered in a group forming a transcription factor response element segment. The segment is at least duplicated in tandem upstream of the ATG start codon. Spacers of 0.2-0.7 kilo base pairs are introduced between the two segments and smaller spacers of about between 9-15 by are introduced between the copies of REs within a segment.04-19-2012
20120094374Micrornas and uses thereof - Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.04-19-2012
20130210134Hybrid Superparamagnetic Iron Oxide Nanoparticles and Polyethylenimine as a Magnetocomplex for Gene Transfection - Disclosed are the nanoparticle and the method for the same, and the preparing method includes steps of mixing polyethylenimine (PEI) with the poly(acrylic acid)-bound iron oxide (PAAIO) to form a PEI-PAAIO polyelectrolyte complex (PEC) and mixing the PEI-PAAIO PEC with genetic material such as plasmid DNA to form the PEI-PAAIO/pDNA magnetic nanoparticle. The PEI-PAAIO/pDNA magnetoplex is highly water dispersible and suitable for long term storage, shows superparamagnetism, low cytotoxicity, high stability and nice transfection efficiency, and thus the PEI-PAAIO PEC can replace PEI as a non-viral gene vector.08-15-2013

Patent applications in class VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)